COMBINATION CHEMOTHERAPY WITH METHOTREXATE, VINCRISTINE, CISPLATINUM, CYCLOPHOSPHAMIDE, ADRIAMYCIN, AND BLEOMYCIN (MVP-CAB) FOR METASTATIC UROTHELIAL CANCER
-
- Fujii Akio
- Department of Urology, Hyogo Medical Center for Adult Disease
-
- Oka Nobutoshi
- Department of Urology, Hyogo Medical Center for Adult Disease
-
- Miyasaki Shigenori
- Department of Urology, Hyogo Medical Center for Adult Disease
-
- Higuchi Akihiro
- Department of Urology, Hyogo Medical Center for Adult Disease
-
- Itoh Noboru
- Department of Urology, Shakaihoken Kobe Chuo Hospital
-
- Okamoto Yasuyuki
- Department of Urology, Shakaihoken Kobe Chuo Hospital
-
- Tanaka Hiroyuki
- Department of Urology, Shakaihoken Kobe Chuo Hospital
-
- Hiro-oka Kyubei
- Department of Urology, Kansai Rosai Hospital
-
- Shimatani Nobori
- Department of Urology, Kansai Rosai Hospital
-
- Inoue Takao
- Department of Urology, Kansai Rosai Hospital
-
- Tachibana Yuji
- Department of Urology, Kansai Rosai Hospital
-
- Izumi Takehiro
- Department of Urology, Kasai City Hospital
-
- Yamada Yuji
- Department of Urology, Kasai City Hospital
-
- Tomioka Osamu
- Department of Urology, Himeji Red Cross Hospital
-
- Morishita Shin-ichi
- Department of Urology, Himeji Red Cross Hospital
-
- Yamanaka Kunito
- Department of Urology, Himeji Red Cross Hospital
-
- Nakamura Ichiro
- Department of Urology, Nishiwaki City Hospital
Bibliographic Information
- Other Title
-
- 尿路上皮腫瘍転移例に対する METHOTREXATE, VINCRISTINE, CISPLATINUM, CYCLOPHOSPHAMIDE, ADRIAMYCIN, BLEOMYCIN 併用療法MVP-CAB療法
Search this article
Abstract
We studied 31 patients with bidimensionally measurable metastases of urothelial cancer who were treated with a planned regimen (20mg/m2 methotrexate, 0.6mg/m2 vincristine, 500mg/m2 cyclophosphamide, 20mg/m2 adriamycin, and 30mg bleomycin on day 1, and 50mg/m2 cisplatinum on day 2) in cycles given every 3 weeks. CR was achieved in 4 patients (13%) and PR in 17 patients (55%). The response rates according to the disease characteristics were 71% for TCC, 33% for SCC, 67% for renal pelvis tumors, 67% for bladder tumors, 73% for lung metastases, 67% for liver metastases, and 67% for lymph node metastases. The median response duration and the number of cycles of therapy were 32 months/3 cycles for patients with a CR and 6 months/6 cycles for those with a PR. The median duration of survival was 32 months (range: 3-46) in CR, 11 months (range: 1-37) in PR, and 6 months (range: 2-10) in non responders (NC+PD). A significant prolongation of survival was noted in patients with either CR (p<0.01) or PR (p<0.05). Then main toxic effects were pulmonary fibrosis and myelosuppression. Two patients aged 73 and 81 died of pulmonary fibrosis. However, it was possible to prevent pulmonary fibrosis by not administering bleomycin to patients over 70 years of age, or to patients with pulmonary dysfunction. WBC count nadirs of <2, 000/m3 were noted in 22 patients (71%). Platelet count nadirs of <5×104/mm3 were noted in 7 patients (23%). However, there were no deaths due to myelosuppression.
Journal
-
- The Japanese Journal of Urology
-
The Japanese Journal of Urology 82 (6), 932-939, 1991
THE JAPANESE UROLOGICAL ASSOCIATION
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282680034604416
-
- NII Article ID
- 110003059619
-
- NII Book ID
- AN00196577
-
- ISSN
- 18847110
- 00215287
-
- PubMed
- 1715415
-
- Data Source
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed